IRLAB Therapeutics AB - Class A

FRA:6IRA (Sweden)   Class A
€ 1.30 (-3.72%) Feb 27
At Loss
P/B:
5.03
Market Cap:
€ 66.93M ($ 72.54M)
Enterprise V:
€ 56.40M ($ 61.13M)
Volume:
-
Avg Vol (2M):
1.92K
Also Trade In:
Volume:
-
At Loss
Avg Vol (2M):
1.92K

Business Description

Description
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
Name Current Vs Industry Vs History
Cash-To-Debt 91.75
Equity-to-Asset 0.79
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.02
Distress
Grey
Safe
Beneish M-Score -2.13
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.47
9-Day RSI 53.74
14-Day RSI 54.62
6-1 Month Momentum % 84.62
12-1 Month Momentum % 33.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.48
Quick Ratio 3.48
Cash Ratio 3.07
Days Sales Outstanding 284.92

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.7
Shareholder Yield % 0.38

Financials (Next Earnings Date:2024-05-08)

FRA:6IRA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

IRLAB Therapeutics AB Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 1.697
EPS (TTM) (€) -0.299
Beta 0.47
Volatility % 93.03
14-Day RSI 54.62
14-Day ATR (€) 0.085393
20-Day SMA (€) 1.27025
12-1 Month Momentum % 33.33
52-Week Range (€) 0.52 - 1.51
Shares Outstanding (Mil) 51.87

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

IRLAB Therapeutics AB Filings

Filing Date Document Date Form
No Filing Data

IRLAB Therapeutics AB Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

IRLAB Therapeutics AB Frequently Asked Questions

What is IRLAB Therapeutics AB(FRA:6IRA)'s stock price today?
The current price of FRA:6IRA is €1.30. The 52 week high of FRA:6IRA is €1.51 and 52 week low is €0.52.
When is next earnings date of IRLAB Therapeutics AB(FRA:6IRA)?
The next earnings date of IRLAB Therapeutics AB(FRA:6IRA) is 2024-05-08.
Does IRLAB Therapeutics AB(FRA:6IRA) pay dividends? If so, how much?
IRLAB Therapeutics AB(FRA:6IRA) does not pay dividend.

Press Release

Subject Date
No Press Release